Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Michael Andrew Morse

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5725-4533; OpenAlex author ID A5074731037. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 0, last author 1)
Trials
1
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

1998: 1 trial · 1999: none · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). Co-author DOI 10.1136/jitc-2023-007883↗
  2. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  3. Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with De… Co-author DOI 10.3892/mco.2021.2348↗
  4. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2018.12.005↗
  5. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  6. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1158/1078-0432.ccr-17-0492↗
  7. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Last author DOI 10.1007/s00280-016-3108-5↗
  8. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗

Trials 1

  1. Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer Study chair NCT00003434↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dung Thi Le · 3 shared papers, 2015–2024 · strength 0.30
  2. Howard W. Bruckner · 2 shared papers, 2019–2021 · strength 0.27
  3. Sant P. Chawla · 2 shared papers, 2019–2021 · strength 0.27
  4. Erlinda Maria Gordon · 2 shared papers, 2019–2021 · strength 0.27
  5. Andrea Wang‐Gillam · 3 shared papers, 2015–2023 · strength 0.25
  6. Muhammad Shaalan Beg · 2 shared papers, 2016–2023 · strength 0.21
  7. Eileen Mary O'Reilly · 1 shared paper, 2024 · strength 0.20
  8. Margaret K. Callahan · 1 shared paper, 2024 · strength 0.20
  9. Padmanee Sharma · 1 shared paper, 2024 · strength 0.20
  10. Janet E. Murphy · 1 shared paper, 2023 · strength 0.15
  11. Hanna Kelly Sanoff · 1 shared paper, 2023 · strength 0.15
  12. Atrayee Basu Mallick · 1 shared paper, 2023 · strength 0.15
  13. Peter J. Hosein · 1 shared paper, 2023 · strength 0.15
  14. Brian Matthew Wolpin · 1 shared paper, 2023 · strength 0.15
  15. Brandon M. Huffman · 1 shared paper, 2023 · strength 0.15
  16. Jill Lacy · 1 shared paper, 2023 · strength 0.15
  17. James M. Cleary · 1 shared paper, 2023 · strength 0.15
  18. Todd S. Crocenzi · 2 shared papers, 2015–2019 · strength 0.11
  19. Dirk G. Brockstedt · 2 shared papers, 2015–2019 · strength 0.11
  20. Herbert J. Zeh · 2 shared papers, 2015–2019 · strength 0.11
  21. Elizabeth M. Jaffee · 2 shared papers, 2015–2019 · strength 0.11
  22. Vincent J. Picozzi · 2 shared papers, 2015–2019 · strength 0.11
  23. Zev A. Wainberg · 1 shared paper, 2019 · strength 0.07
  24. Andrew H. Ko · 1 shared paper, 2019 · strength 0.07
  25. Dan A. Laheru · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.